Mutations of the p53 gene in nasal NK/T-cell lymphoma

Laboratory Investigation

Volumn 80, Issue 4, 2000, Pages 493-499

  Li, Ting ^a   Hongyo, Tadashi ^a   Syaifudin, Mukh ^a   Nomura, Taisei ^a   Dong, Zhiming ^a   Shingu, Norihisa ^a   Kojya, Shizuo ^b   Nakatsuka, Shin Ichi ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NOSE CANCER; PRIORITY JOURNAL; T CELL LYMPHOMA;

EID: 0034049159     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780055     Document Type: Article

References (30)

1. Adamson DJA, Thompson WD, Dawson AA, Bennett B, and Haites NE (1995). p53 mutation and expression in lymphoma. Br J Cancer 72:150-154.
2. Anderson M, Jonsson M, Nielsen LL, Vyberg M, Visfeldt J, Storm HH, and Wallin H (1995). Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles. Cancer Epidemiol Biomarkers Prev 4:765-770.
3. Aozasa K, Ohsawa M, Tajima K, Sasaki R, Maede H, Matsunaga T, and Friedmann I (1989). Nation-wide study of lethal midline granuloma in Japan: frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 44:63-66.
4. Capoulade C, Bressac PB, Lefrere I, Ronsin M, Feunteun J Tursz T, and Wiels J (1998). Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16:1603-1610.
5. Donehower LA, Harrey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel J, and Bradley A (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221.
6. Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P, Tursz T, Liu E, and Raab-Traub N (1992). Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66:3768-3775.
7. Eichel BS, Harrison EGJ, Devine KD, Scanlon PW, and Brown HA (1966). Primary lymphomas of the nose including relationship to lethal midline granuloma. Am J Surg 112:597-605.
8. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, and Dalla-Favera R (1991). p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417.
9. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno A, and Osato T (1990). Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130.
10. Hollstein M, Sidransky D, Vogelstein B, and Harris SR (1991). p53 mutations in human cancers. Science 253:49-53.
11. Hongyo T, Buzard GS, Calvert RJ, and Weghorst CM (1993). 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single strand conformation polymorphism analyses. Nucl Acid Res 21:3637-3642.
12. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF, and Rice JM (1995). Mutations of the k-ras and p53 gene in gastric adenocarcinoma from a high incidence region around Florence, Italy. Cancer Res 55:2665-2672.
13. Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K, and Nomura T (1998). Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer Res 58:1105-1107.
14. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, and Salto H (1992). Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701-2707.
15. Jaffe ES, Chan JKC, Su I-J, Frizzera G, Mori S, Feller AC, and Ho FCS (1996). Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Am J Surg Pathol 20:103-111.
16. Kassel S, Echevaria RA, and Guzzo FP (1969). Midline malignant reticulosis (so-called lethal midline granuloma). Cancer 23:920-935.
17. Levine AJ, Momand J, and Finley CA (1991). The p53 tumor suppressor gene. Nature 351:453-456.
18. Lipford EH Jr, Margolick JB, Longo DL, Fauci AS, Jaffe ES (1988). Angiocentric lymphoproliferative lesions: A clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 72:1674-1681.
19. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RSK, and Dalla-Favera R (1993). p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82: 2289-2295.
20. Martinez DB, Robledo M, Arranz E, Infantes F, Echezarreta G, Marcos B, Sanz C, Rivas C, and Benitez J (1997). Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol 55:1-8.
21. Nakamura H, Said JW, Miller CW, and Koeffer HP (1993). Mutation and expression of p53 in acquired immunodeficiency syndrome-related lymphoma. Blood 82:920-926.
22. Niedobitek G, Rowlands DC, Yong LS, Herbst H, Williams A, Hall P, Padfield J, Rooney N, and Jones EL (1993). Overexpression of p53 in Hodgkin's disease: lack of correlation with Epstein-Barr virus infection. J Pathol 169:207-212.
23. Ohsawa M, Nakatsuka S, Kanno H, Miwa H, Kojya S, Harabachi Y, Yang WI, and Aozasa K (1999). Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer 81:865-870.
24. Quintanilla-Martinez L, Guerrero I, Franklin JL, Naresh KN, Krenacs L, Rama-Rao C, Bhatia K, Magrath IT, and Raffeld M (1998). Nasal NK/T-cell lymphoma from Peru. High prevalence of p53 overexpression. Mod Pathol 11:139A.
25. Szekely L, Selivanova G, Magnusson KP, Klein G, and Wiman KG (1993). EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90:5455-5459.
26. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, and Anderson M (1994). p53 mutation hotspot in radon-associated lung cancer. Lancet 8:86-87.
27. Tomita Y, Ohsawa M, Mishiro Y, Kubo T, Maeshiro N, Kojya S, Noda Y, and Aozasa K (1995). The presence and sub-type of Epstein-Barr virus in B- and T-cell lymphomas of the sino-nasal region from the Osaka and Okinawa districts of Japan. Lab Invest 73:190-196.
28. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, Orradre JL, Garcia P, Lopez C, and Martinez P (1993). The expression of p53 protein in non-Hodgkin's lymphoma is not always dependent on p53 gene mutations. Blood 82:3151-3156.
29. Weiss LM, Chen YY, Liu XF, and Shibata D (1991). Epstein-Barr virus Hodgkin's disease: a correlative in situ hybridization and polymerase-chain-reaction study. Am J Pathol 139: 1259-1265.
30. Zhang Q, Gutsch D, and Kenney S (1994). Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 14:1929-1938.